Methyl-cytosine-phosphate-guanine (CpG)-binding domain (MBD) proteins are bound to hypermethylated promoter CpG islands of tumor suppressor genes in human cancer cells, although a direct causal relationship at the genome-wide level between MBD presence and gene silencing remains to be demonstrated. To this end, we have inhibited the expression of MBD proteins in HeLa cells by short hairpin RNAs; and studied the functional consequences of MBD depletion using microarray-based expression analysis in conjunction with extensive bisulfite genomic sequencing and chromatin immunoprecipitation. The removal of MBDs results in a release of gene silencing associated with a loss of MBD occupancy in 5 0 -CpG islands without any change in the DNA methylation pattern. Our results unveil new targets for epigenetic inactivation mediated by MBDs in transformed cells, such as the cell adhesion protein c-parvin and the fibroblast growth factor 19, where we also demonstrate their bona fide tumor suppressor features. Our data support a fundamental role for MBD proteins in the direct maintenance of transcriptional repression of tumor suppressors and identify new candidate genes for epigenetic disruption in cancer cells.
Methyl-cytosine-phosphate-guanine (CpG)-binding domain (MBD) proteins are bound to hypermethylated promoter CpG islands of tumor suppressor genes in human cancer cells, although a direct causal relationship at the genome-wide level between MBD presence and gene silencing remains to be demonstrated. To this end, we have inhibited the expression of MBD proteins in HeLa cells by short hairpin RNAs; and studied the functional consequences of MBD depletion using microarray-based expression analysis in conjunction with extensive bisulfite genomic sequencing and chromatin immunoprecipitation. The removal of MBDs results in a release of gene silencing associated with a loss of MBD occupancy in 5 0 -CpG islands without any change in the DNA methylation pattern. Our results unveil new targets for epigenetic inactivation mediated by MBDs in transformed cells, such as the cell adhesion protein c-parvin and the fibroblast growth factor 19, where we also demonstrate their bona fide tumor suppressor features. Our data support a fundamental role for MBD proteins in the direct maintenance of transcriptional repression of tumor suppressors and identify new candidate genes for epigenetic disruption in cancer cells.
Introduction
During the past few years, considerable attention has been focused upon the possibility that proteins that 'read' DNA methylation patterns may play a central role in cellular transformation. This is mainly due to the recognition that DNA hypermethylation of the promoter cytosine-phosphate-guanine (CpG) islands of tumor suppressor genes, and resulting gene inactivation, represent a major event in tumor etiology and progression (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) . The methyl-CpG-binding domain (MBD) family of proteins is the largest group of these factors that bind methylated DNA, and their exact role in the epigenetic silencing of tumor suppressor genes has functional and translational consequences that need to be clarified (Ballestar and Esteller, 2005; Fatemi and Wade, 2006) . The MBD family of proteins is composed of five bona fide members, MeCP2, MBD1, MBD2, MBD3 and MBD4, which share an MBD that allows them to bind methylated DNA (Hendrich and Bird, 1998; Ballestar and Esteller, 2005; Fatemi and Wade, 2006) . With the exception of MBD4, which is involved in DNA repair , and MBD3, whose MBD is unable to bind methylated DNA selectively (Saito and Ishikawa, 2002; Fraga et al., 2003) , MBDs couple DNA methylation with transcriptional repression through association with histone deacetylases (HDACs; Jones et al., 1998; Nan et al., 1998; Wade et al., 1999) and histone methyltransferases (Fujita et al., 2003; Fuks et al., 2003) . These properties have led them to being proposed as having a major role in the aberrant epigenetic silencing of tumor suppressor genes (Ballestar and Esteller, 2005; Fatemi and Wade, 2006) .
Genetic analysis of MBD proteins has shown that most single MBD-deficient mouse models do not exhibit dramatic phenotypes Hendrich et al., 2001; Zhao et al., 2003) . However, detailed analysis shows that subtle but important changes are associated with deficiency in individual MBD proteins. For instance, loss of MBD2 is associated with a significant change in the abundance of transcripts for certain cytokines that are crucial to the process of T-lymphocyte differentiation (Hutchins et al., 2002) . Crossing Mbd2-null mice with Apc Min also inhibits the development of intestinal adenomas (Sansom et al., 2003) and MeCP2 is required for prostate cancer cell growth (Bernard et al., 2006) . In addition, disruption of the MeCP2 gene in Rett syndrome samples from mouse models (Jordan et al., 2007) or human patients is associated with upregulation of a subset of genes as a result of the loss of interaction of MeCP2 with methylated CpG sites at the promoter region.
Since DNA methylation patterns differ dramatically between cancer cells and their normal counterparts (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) , it is likely that the distribution and, ultimately, the biological relevance of MBD proteins are also significantly different in normal and transformed cells. In normal cells, promoter CpG islands are mostly unmethylated, with the exception of those of imprinted genes, X-chromosome genes in females and a number of tissue-specific genes (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) . In contrast, cancer cells are characterized by the generation of specific patterns of hypermethylation at the promoter CpG islands of tumor suppressor genes (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) . DNAmethylated heterochromatic sequences are probably the primary binding site for MBD proteins in normal cells, as suggested by the fact that MeCP2 is enriched in pericentromeric heterochromatin in murine cells, in accordance with its content of major satellite DNA, the largest fraction of methylated DNA sequences in mice (Lewis et al., 1992) . Another normal set of targets for MBDs are imprinted genes, where MBDs associate with the differentially methylated allele (Fournier et al., 2002) . In cancer cells, the hypermethylated promoter CpG islands of tumor suppressor genes constitute new and aberrant targets for MBD proteins and accumulated evidence indicates that hypermethylation of tumor suppressor genes is accompanied by association of MBDs (Magdinier and Wolffe, 2001; Nguyen et al., 2001; Bakker et al., 2002; Koizume et al., 2002; Ballestar et al., 2003; Lopez-Serra et al., 2006) . Given the association of MBDs with HDACs and methyltransferases and their DNA methylation-dependent effects on gene transcription, their essential contribution to the epigenetic silencing of tumor suppressor genes is generally accepted, even though no formal evidence has been presented to date.
We have addressed this issue in transformed cells by studying the global gene expression patterns upon knocking down MBDs using short hairpin RNA molecules (interfering RNA, RNAi) targeting for individual (MeCP2, MBD1 and MBD2) and combined MBDs. Our results show that removal of MBDs cause a release in gene silencing without changing the underlying DNA methylation patterns of the respective DNA regulatory regions. Our comprehensive epigenomic screening also identifies new candidate genes undergoing transcriptional silencing in human cancer cells in association with CpG island promoter hypermethylation and MBD occupancy. Functional analysis of these genes, including colony formation assays and the use of xenografts in nude mice, indicates their putative tumorsuppressing properties. Therefore, these data underline the critical role of MBDs in the maintenance of epigenetic gene silencing and the usefulness of MBDdepletion strategies to 'catch' new hypermethylated genes in human cancer.
Results
Removal of MBD proteins results in release of epigenetic gene silencing To demonstrate functionally the direct role of MBDs in gene silencing, we carried out a systematic depletion of MBD proteins in HeLa cells (human cervical cancer) in conjunction with comprehensive expression microarray analyses. We interfered with the expression of the three MBD proteins (MeCP2, MBD1 and MBD2) that have a functional MBD and for which association with histone modification enzymes and transcriptional repression properties has been demonstrated ( Figure 1a ; Jones et al., 1998; Nan et al., 1998; Ng et al., 1999 Ng et al., , 2000 . Seven different RNA interference experiments were performed: single MeCP2, MBD1 and MBD2, combined MeCP2/MBD1, MeCP2/MBD2 and MBD1/ MBD2, and the triple MeCP2/MBD1/MBD2 combination. First, we confirmed the robust depletion of the corresponding MBD proteins after transient transfection with RNAi oligonucleotides at both the RNA (Figures 1b and c) and protein levels (Figure 1d ) for the single, double and triple combinations. Upon depletion of one single MBD, we did not observe any significant changes in the expression of the other members of the MBD family (Figures 1b and d) . No significant changes in the global 5-methylcytosine DNA content determined by high-pressure liquid chromatography were observed upon MBD depletion (Supplementary Figure S1 ). From the HeLa-untreated and MBD-interfered cells, total RNA was extracted, reverse transcribed, hybridized to cDNA microarrays and the data were analysed, as described in 'Materials and methods'.
We observed a release of transcriptional silencing upon depletion of MBD proteins by RNAi (Figure 2a) . Of the 6386 genes represented in the expression array, 967 (15%) experienced an expression change between untreated and triple MBD-depleted cells (Figure 2a ). Most importantly, 99% (964 of 967) of these differences corresponded to increased transcription of each respective gene (Figure 2a) . We observed the presence of a CpG island in their 5 0 -ends in 74.27% (716 of 964) of the described genes. Supplementary Table S1 lists the 964 genes upregulated upon triple-MBD interference in HeLa cells. For single MBD interference, MBD2 depletion was the protein most commonly involved in the observed release of gene silencing by far (Figure 2a) . The presence of a putative described MeCP2-binding motif, (A/T)>4 (Klose et al., 2005) , in the 5 0 -end regions of reactivated genes upon single MBD depletion was similar for MeCP2 (29%, 54 of 187 genes), MBD1 (25%, 66 of 264 genes) and MBD2 (24%, 219 of 913). Downregulated genes upon MBD removal were almost absent (Figure 2a) .
Genes undergoing silencing release upon MBD removal are characterized by promoter CpG island hypermethylation and MBD occupancy Among the hundreds of gene upregulated following MBD interference, imprinted genes and those on the X-chromosome (HeLa cells are derived from a female donor) are obvious candidates for MBD transcriptional repression associated with promoter CpG island hypermethylation (Ballestar and Esteller, 2005; Fatemi and Wade, 2006) . A list of genes from this upregulated category upon MBD depletion is shown in Supplementary Table S2 . We have instead focused on those genes lying in a different category: putative tumor suppressor genes that are epigenetically inactivated in human cancer (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) . Thus, we have randomly selected 26 5 0 -CpG island-containing genes, from different cellular pathways disrupted in cancer cells (Hanahan and Weinberg, 2000) , which are at least twofold overexpressed in the triple MBD-interfered cells for further DNA methylation and MBD-binding studies. These candidate genes are described in Supplementary  Table S3 . Extensive bisulfite genomic sequencing of the promoter CpG islands of these genes reveals dense DNA hypermethylation in 38% (10 of 26) of these candidate genes in HeLa cells (Figures 2b and 3a) . The remaining genes with MBD depletion-mediated upregulation, but unmethylated promoter CpG islands, may represent either targets indirectly regulated by MBD proteins, the presence of DNA methylation sites outside the canonical proximal promoter CpG island or methylation-independent targets of MBD proteins, particularly those related to the CxxC motifs of MBD1 (Fujita et al., 1999) . Genes previously described as hypermethylated and bound by MBDs in HeLa cells, such as CDH1 and PR (Lopez-Serra et al., 2006) , were also found reactivated upon triple MBD depletion (data not shown), however, for other hypermethylated MBD depletion in transformed cells L Lopez-Serra et al genes in HeLa cells, such as CHFR and TIPM3, which do not present occupancy by MeCP2, MBD1 or MBD2 in these cells (Lopez-Serra et al., 2006) , the triple MBD knockdown approach was not able to restore their expression.
To establish a functional link between MBDs and DNA methylation-associated transcriptional silencing in the candidate genes, it is essential to demonstrate physical occupancy by MBDs in these hypermethylated 5 0 -CpG islands. To accomplish this aim, we performed chromatin immunoprecipitation (ChIP) analyses of the 10 genes for which we had observed dense CpG island hypermethylation and of 5 unmethylated genes in HeLa cells. We consistently observed that MBDs were exclusively bound to the hypermethylated promoter CpG islands (Figure 3b) , while unmethylated 5 0 -CpG islands were found to be devoid of MBDs (Supplementary Figure S2) , reinforcing the notion of the in vivo preference of MBD proteins for DNA-methylated sequences. Importantly, treatment of HeLa cells with a DNA demethylating agent (5 0 -aza-2-deoxycytidine) induced the release of MBDs from the described CpG islands (Figure 3c ). Both sets of data reinforce the notion of the in vivo preference of MBD proteins for DNA-methylated sequences.
Finally, we considered whether the removal of the MBDs by the RNA interference approach affected the 5 0 -CpG island DNA methylation patterns of these candidate genes, in which we had demonstrated MBD occupancy by ChIP. We found the same DNA methylation pattern in these sequences in the untreated and MBD-interfered HeLa cells-a densely hypermethylated CpG island (Figure 3a ).
MBD-bound hypermethylated genes contribute to cell transformation and human tumorigenesis
The acceptance of the epigenetic silencing of tumor suppressor genes, such as p16
INK4a
, hMLH1 and BRCA1, by CpG island promoter hypermethylation as a major hallmark of human transformed cells (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) prompted us to investigate the contribution of the newly identified MBD target genes to tumorigenesis. First, we studied the 10 candidate genes showing CpG island methylation and MBD occupancy in HeLa cells to determine whether the presence of hypermethylation was a cancer-specific event. Extensive bisulfite genomic sequencing and methylation-specific PCR analyses for the corresponding 5 0 -CpG islands showed that for g-parvin (PARVG), fibroblast growth factor 19 (FGF19), protein tyrosine phosphatase-like N precursor (PTPRN), collagen type XI a-2 (COL11A2) and latent transforming growth factor b-binding protein (LTBP) 3, CpG island hypermethylation was commonly observed in human cancer cell lines (n ¼ 23) from different tumor types (cervix, breast colon, lung, leukemia and MBD depletion in transformed cells L Lopez-Serra et al lymphoma), but was absent from all normal tissues studied (n ¼ 13), indicating its cancer-specific profile (Figure 4a ; Supplementary Table S4 ). In contrast, TUBA-2, QKI, GJB3, KRT14 and TSSC4 5 0 -CpG island methylation was observed in both cancer cell lines and normal tissues (Supplementary Figure S3) . No particularly different MBD-binding profile was observed in the cancer-specific compared with the normal hypermethylated CpG islands (data not shown). For the MBD-bound cancer-specific hypermethylated genes, we further demonstrated that not only the presence of CpG island hypermethylation was associated with the lack of each respective mRNA transcript (Figure 3b ), but also that treatment of the cancer cells with the DNA demethylating agent 5-aza-2 0 -deoxycytidine restored gene expression (Figure 4b) , providing a further link between DNA methylation, MBD binding and transcriptional silencing.
Furthermore, to determine whether these genes display putative tumor suppressor features, as do other classical hypermethylated genes (for example, p16
INK4a , hMLH1 and BRCA1), we adopted a double approach, in vitro and in vivo, for two illustrative cases, PARVG and FGF19. First, we transfected PARVG or FGF19 in HeLa cells, which have DNA methylation/MBDassociated silencing of both genes, as demonstrated above, and assessed cell viability using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (see 'Materials and methods'). Restoration of PARVG or FGF19 expression, demonstrated in Figure 5a , caused a marked reduction of the viability of HeLa cells (Figure 5b) . We completed the demonstration of the growth-inhibitory features of PARVG and FGF19 in colony focus assays and nude mouse models. In the colony formation assay, we used G418 selection after transfecting the HeLa cell line with the PARVG or FGF19 gene or the empty vector (Figure 5c ). PARVG or FGF19 reexpression revealed tumor suppressor activity whereby there were marked reductions of 82 and 90%, respectively, in colony formation density with respect to the empty vector (Figure 5c ). We next tested the ability of PARVG-or FGF19-transfected HeLa cells to form tumors in nude mice compared with empty vector-transfected cells (Figure 5d ). Cells transfected with the empty vector formed tumors rapidly, but cells infected with the PARVG or FGF19 expression vector had much lower tumorigenicity (Figure 5d ).
Finally, we observed that the presence of 5 0 -CpG island hypermethylation for PARVG and FGF19, in addition to the other three cancer-specific hypermethylated genes identified using our MBD-depletion microarray approach (PTPRN, COL11A2 and LTBP), was not an in vitro culture phenomenon of the transformed cells. The analyses of a comprehensive collection of primary human tumor samples (n ¼ 223) from the most common tissue types (breast, colon, lung, cervix, leukemia and lymphoma) demonstrated that promoter CpG island hypermethylation of these newly identified MBD targets is a common event in human cancer (Figure 6 ; Supplementary Table S5) .
Discussion
The most widely studied epigenetic modification in humans is the cytosine methylation of DNA within the dinucleotide CpG. A total of 3-6% of all cytosines are methylated in normal human DNA (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) . Potentially 'methylable' CpG dinucleotides are not randomly distributed in the human genome; instead, CpG-rich regions known as CpG islands, which span the 5-end region (promoter, untranslated region and exon 1) of many genes, are usually unmethylated in normal cells. This unmethylated status is linked to the ability of CpG island-containing genes to be transcribed in the presence of the necessary transcriptional activators. In cancer cells, the transcriptional silencing of tumor suppressor genes by CpG island promoter hypermethylation is key to the tumorigenic process, contributing to all of the typical hallmarks of a cancer cell (Hanahan and Weinberg, 2000) that result from tumor suppressor inactivation (Jones and Laird, 1999; Herman and Baylin, 2003; Esteller, 2007) . Proteins of the MBD family are thought to be involved in promoter CpG island hypermethylation-associated silencing due to their ability to silence genes through the recruitment of HDAC and methyltransferase activities to methylated DNA (Jones et al., 1998; Nan et al., 1998; Wade et al., 1999; Fujita et al., 2003; Fuks et al., 2003) . Despite the accumulated evidence demonstrating the presence of MBD proteins at CpG island-methylated promoters of tumor suppressor (Magdinier and Wolffe, 2001; Nguyen et al., 2001; Bakker et al., 2002; Koizume et al., 2002; Ballestar et al., 2003; Lopez-Serra et al., 2006) , their direct involvement in the silenced gene status has not been functionally demonstrated. Here, we show the direct involvement of MBDs in the maintenance of the silenced status of a significant number of genes in transformed cells model. The removal of three MBD proteins (MeCP2, MBD1 and MBD2) singly or in combination results in the release of gene silencing mainly associated with DNA-methylated 5 0 -regulatory regions that were bound by the corresponding MBD(s) in untreated cells. Most importantly, the upregulation of these MBD-associated genes occurs without any change in the DNA methylation pattern of the underlying DNA sequence.
MBD2 appears to be the MBD family member with the greatest effect on gene silencing. These results are in agreement with the preliminary findings of our group and others obtained using several models Fraga et al., 2003; Sansom et al., 2003) . In vitro, MBD2 is the MBD protein with the highest biochemical affinity for methylated DNA . In vivo ChIP experiments with MBDs associated with genomic CpG island arrays (ChIP-on-CHIP) show that MBD2 binds to the largest number of CpG islands in breast cancer cells . Interestingly, crossing Mbd2-null mice with Apc Min colon adenoma-prone mice results in the inhibition of intestinal tumor development (Sansom et al., 2003) , suggesting that the loss of MBD2 might 'trigger' a comprehensive loss of silencing of hypermethylated tumor suppressor genes and thus induce inhibition of cell growth and transformation.
Our results suggest that the removal of the MBD proteins associated with an expression microarray approach is also a useful strategy for identifying new gene targets undergoing DNA methylation-associated silencing in transformed cells. The use of candidate gene approaches (Magdinier and Wolffe, 2001; Nguyen et al., 2001; Bakker et al., 2002; Koizume et al., 2002; Lopez-Serra et al., 2006) and ChIP-on-CHIP strategies had already established important genes whose transcriptional inactivation was mediated by MBD binding to the corresponding hypermethylated promoters, but we have gone one step further by depleting the MBDs, the 'interpreters' of the DNA methylation signal itself. We have also shown that the CpG island hypermethylation of these newly identified genes is not a unique feature of HeLa cells, but is also common in human tumorigenesis, being found in cancer cell lines and human primary tumors from different organs and tissues. The list of epigenetically silenced genes revealed covers most of the disrupted pathways of transformed cells (Hanahan and Weinberg, 2000) , such as signal transduction mediated by the families of tyrosine phosphatases and transforming growth factor-b and their regulators, exemplified by PTPRN (Lan et al., 1994) and LTBP3 (Yin et al., 1995) , respectively, or cell matrix adhesion, exemplified by PARVG (Olski et al., 2001 ). In the case of the later gene and of FGF19 we 
Materials and methods

Human cancer cell lines and primary tumors
HeLa cells were cultured in Dulbecco's modified Eagle's medium with 4.5 g l À1 glucose and L-glutamine supplemented with 10% of fetal calf serum by Hyclone and 1% penicillin/ streptomycin in a humidified 37 1C, 5% CO 2 incubator. All the remaining human cancer cell lines were grown as previously described (Lopez-Serra et al., 2006) . HeLa cells were treated with 5-aza-2-deoxycytidine (1 mmol l
À1
) for 72 h. All cell lines (n ¼ 23) were obtained from the American Type Culture Collection (Rockville, MD, USA). Tissue samples of human primary tumors (n ¼ 223) and corresponding normal tissues (n ¼ 13) were all obtained at the time of the clinically indicated procedures.
RNA interference of MBD proteins
MeCP2-, MBD1-and MBD2-specific small RNAi were designed and synthesized by Qiagen (Valencia, CA, USA). Two different RNAi duplexes, recognizing two different sequences, were used against each of the MBDs genes (Supplementary Table S6 ). As control, we used scramble RNAi (Qiagen). Transfections were carried out using oligofectamine (Invitrogen, Carlsbad, CA, USA) and cells were recollected 42 h after transfection. MeCP2, MBD1 and MBD2 content was analysed by western blotting, conventional reverse transcription-PCR (RT-PCR) and quantitative RT-PCR.
Microarray analysis
The profiles of gene expression were determined by a cDNA microarray that contains 7237 sequencevalidated IMAGE clones, including 5253 clones representing known genes and the remaining 1984 clones representing expressed sequence tags (ESTs). Time-course experiments were performed using an extended version of the expression microarray in which cancer-related clones (n ¼ 2489) were printed twice. Total RNAs were converted to double-stranded cDNA using the superscript choice system (Life Technologies, Gaithersburg, MD, USA) using oligo-dT primer containing a T7 RNA polymerase promoter. Fluorescent first-strand cDNA is made in the presence of Cy5-dCTP (red) for the sample or Cy3-dCTP (green) for a universal RNA standard. Slides are simultaneously hybridized with labeled sample and standard. Slides are then scanned for Cy3 and Cy5 fluorescence using Scanarray 5000 XL (GSI Lumonics Kanata, Ontario, Canada) and quantified using the Quantarray software (GSI Lumonics) and/or GenePix Pro 4.0 software (Axon Instruments Inc., Union City, CA, USA). Data were preprocessed in the following way: (1) log-transformation to obtain symmetrical ratios, (2) replicate handling (removing inconsistent replicates and merging the remaining ones), (3) missing value management, (4) flat pattern filtering by standard derivation and (5) pattern standardization by subtracting the pattern average and dividing the values by the standard derivation. Genes with an average fold change of more than two were considered as differentially expressed between both groups of comparison.
DNA methylation analysis
We carried out bisulfite modification of genomic DNA as described previously (Lopez-Serra et al., 2006) . We established the methylation status of gene promoters by PCR analysis of bisulfite-modified genomic DNA using two procedures. First, Figure 6 Methyl-CpG-binding domain (MBD)-bound hypermethylated genes contribute to human carcinogenesis. Detection of gparvin (PARVG) and fibroblast growth factor 19 (FGF19) 5 0 -cytosine-phosphate-guanine (CpG) island methylation in primary tumors from different organs and tissues (cervix, breast, colon, lung, leukemia and lymphoma) using methylation-specific PCR analysis. The presence of a PCR band under lanes M or U indicates methylated or unmethylated genes, respectively. Normal lymphocytes (NL) are used as positive controls for unmethylated DNA and in vitro methylated DNA (IVD) is used as positive control for methylated DNA.
all genes studied were analysed by bisulfite genomic sequencing of their corresponding promoter CpG islands (Lopez-Serra et al., 2006) . Both strands were sequenced. The second analysis used methylation-specific PCR analyses (Herman et al., 1996) . Placental DNA treated in vitro with Sss I methyltransferase was used as positive control for all methylated genes. We designed all of the bisulfite genomic sequencing and methylation-specific PCR primers according to genomic sequences around presumed transcription start sites of investigated genes. Primer sequences are mentioned in Supplementary Table S6. PCR conditions for methylation analysis are available upon request.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed as previously described Lopez-Serra et al., 2006) . Fixation was performed with 1% formaldehyde and sonication was optimized to obtain 300-1000 bp chromatin fragments. Antibodies against each of the MBDs studied were obtained from Abcam, Cambridge, UK. PCR amplification was carried in 25 ml with specific primers for each of the analysed promoters. For each promoter, the sensitivity of PCR amplification was evaluated on serial dilutions of total DNA collected after sonication (input fraction). After PCR amplifications of the input, as positive control, and the bound fraction for each antibody, samples were run in 2% agarose gels. Primer sequences are mentioned in Supplementary Table S6 .
RT-PCR expression analysis
We reverse transcribed total RNA (2 mg) treated with DNase I (Ambion, Austin, TX, USA) using Oligo(dT) primer with SuperScript Reverse Transcriptase (Life Technologies). We used 100 ng cDNA for PCR amplification and amplified the candidate genes with multiple cycle numbers (20-35 cycles) to determine the appropriate conditions for obtaining semiquantitative differences in their expression levels. RT-PCR primers were designed between different exons to avoid residual genomic DNA amplification. Glyceraldehyde-3-phosphate dehydrogenase was amplified as internal control to test cDNA quality and loading accuracy. Primer sequences are mentioned in Supplementary Table S6 .
Cell transfection PARVG and FGF19 cDNAs were cloned into pCDNA3 expression vector (Invitrogen). Transfection of HeLa cell line was performed by cell electroporation (Gene Sensor II, Bio-Rad, Hercules, CA, USA) at 250 mV, 950 mF and maximal capacitance. After electroporation cells were cultured for 2 days in 20% fetal bovine serum medium and were then selected in complete medium supplemented with 1 mg ml À1 G418. Expression of FGF19 and PARVG were tested by western blotting using antibodies raised against FGF19 (Upstate, Bedford, MA, USA, 1:500) and PARVG (courtesy of Dr Fa¨ssler laboratory, 1:2500), respectively.
Western blotting
Total protein was separated on 10% SDS-polyacrylamide gel electrophoresis gel and blotted onto a polyvinylidene difluoride membrane of 45 mm pore size (Immobilon PSQ; Millipore, Bedford, MA, USA). The membrane was blocked in 5% milk phosphate-buffered saline with 0.1% Tween-20 (PBS-Tween) and immunoprobed with antibodies raised against PARVG and FGF19 The secondary antibodies used were rabbit antigoat conjugated to horseradish peroxidase (1:3000) and goat anti-rabbit horseradish peroxidase (1:3000) (both from Amersham Biosciences, Piscataway, NJ, USA), respectively.
Colony formation and cell viability assays Colony formation assays were performed adding transfected cells to a medium containing 80% methylcellulose (StemCell Technologies, Vancouver, BC, Canada) and 20% conditioned medium from HeLa cell cultures, and 600 mg ml À1 G418. The mixture was then placed in a six-well plate and incubated for 15 days. Colonies containing more than 20 cells were scored as positive. Cell viability was determined by the MTT assay. Aliquots of 1.5 Â 104 cells were plated in 96-well microdilution plates. Following overnight cell adherence, experimental media containing the drugs or control media was added to appropriate wells. After 48 h, the media was replaced by drug-free fresh media (100 ml per well) containing 50 mg of MTT. After a 3 h incubation at 37 1C in 5% CO 2 atmosphere, the MTT was removed and MTT formazan crystals were dissolved in dimethyl sulfoxide (100 ml per well). Absorbance at 570 nm was determined on an automatized microtiter plate reader. It was established that optical density was directly proportional to the cell number up to the density reached by the end of the assay.
Mouse xenograft model
Female athymic nude mice (6-week old) were used for tumor xenografts. Animals were randomly separated in three groups of seven specimens each (those injected with HeLa cells carrying the empty vector as a control, those injected with HeLa cells expressing FGF19 and those injected with HeLa cells expressing PARVG). Both flanks and a shoulder of each animal were injected subcutaneously with 10 6 (mock and FGF19 þ ) or 10 6 (PARVG þ ) cells in a total volume of 200 ml of PBS. Tumor development at the site of injection was evaluated daily. Mice were killed 28 days after injection.
